Product Images Votrient

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Votrient NDC 0078-0670 by Novartis Pharmaceuticals Corporation, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

votrient 01

votrient 01

This is a description for a medication called Votrient, which comes in tablet form. The package contains 120 tablets, each with a strength of 200 mg. The manufacturer of the medication is Novartis, and the product is identified as NDG 0078-0670-00. The medication contains pazopanib and is produced in Singapore.*

The following chemical structure for VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide monohydrochloride. It has the molecular formula C21H23N7O2S•HCl and a molecular weight of 473.99. - votrient 02

The following chemical structure for VOTRIENT (pazopanib) is a tyrosine kinase inhibitor (TKI). Pazopanib is presented as the hydrochloride salt, with the chemical name 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide monohydrochloride. It has the molecular formula C21H23N7O2S•HCl and a molecular weight of 473.99. - votrient 02

Figure 1. Kaplan-Meier Curve for Progression-free Survival in RCC by Independent Assessment for the Overall Population (Treatment-naïve and Cytokine Pre-treated Populations) - votrient 03

Figure 1. Kaplan-Meier Curve for Progression-free Survival in RCC by Independent Assessment for the Overall Population (Treatment-naïve and Cytokine Pre-treated Populations) - votrient 03

Not available.*

Figure 2. Kaplan-Meier Curve for Progression-free Survival in STS by Independent Assessment for the Overall Population - votrient 04

Figure 2. Kaplan-Meier Curve for Progression-free Survival in STS by Independent Assessment for the Overall Population - votrient 04

PRINCIPAL DISPLAY PANELNDC 0078-0670-66Votrient(pazopanlb)Tablets200 mg120 TabletsRx Only - votrient 05

PRINCIPAL DISPLAY PANELNDC 0078-0670-66Votrient(pazopanlb)Tablets200 mg120 TabletsRx Only - votrient 05

This is a description of the drug Votrient (pazopanib) manufactured by NovarTIs Llaas. The text includes instructions not to use it in pregnancy and mentions a tablet safety seal under the cap. The rest of the text is not-readable and contains non-English characters, so additional information cannot be provided.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.